Fennec Pharmaceuticals (TSE:FRX) Reaches New 1-Year High - Still a Buy?

Key Points

• Fennec Pharmaceuticals Inc. shares reached a new 52-week high trading at C$13.75, up from a previous close of C$13.42.
• The company has a market capitalization of C$376.01 million and is focused on developing its lead product, PEDMARK, to prevent hearing loss from chemotherapy.
• Fennec has a notable debt-to-equity ratio of -620.83 and a high liquidity position with current and quick ratios of 7.80 and 10.17, respectively.

Shares of Fennec Pharmaceuticals Inc. (TSE:FRX - ) hit a new 52-week high on Monday . The stock traded as high as C$13.75 and last traded at C$13.75, with a volume of 324 shares traded. The stock had previously closed at C$13.42.

Fennec Pharmaceuticals Price Performance

The firm has a market capitalization of C$376.01 million, a P/E ratio of -30.02 and a beta of 2.48. The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17. The stock's fifty day simple moving average is C$12.08 and its 200 day simple moving average is C$10.65.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.